Personalized mRNA Cancer Vaccine Combined With Immunotherapy Cuts Melanoma Recurrence Risk by 42%
Source Summary
A phase 3 trial presented at ESMO Congress 2026 found that intismeran autogene, a personalized mRNA-based cancer vaccine, combined with pembrolizumab reduced the risk of recurrence or death by 42% in high-risk melanoma patients after surgery. The vaccine was compared with pembrolizumab alone in the INTerpath-001 trial.
Why it matters
The trial demonstrates a clinically significant improvement in recurrence-free and overall survival outcomes for high-risk melanoma patients when combining personalized immunotherapy with standard checkpoint inhibition.
